EUVIMEDEUVIMED entdecken
LeserbriefOpen Access

Genetic Basis of Relapse after GPRC5D-Targeted CAR T Cells

Xiaoli Mi, Alex Penson, Omar Abdel-Wahab, Sham Mailankody

New England Journal of Medicine · 2023

DOI: 10.1056/nejmc2308544 ↗

Kurz gefasst

Leserbrief in der Zeitschrift New England Journal of Medicine, 2023. Verfasst von Xiaoli Mi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, NY mailanks@mskcc.org. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Multiple Myeloma, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Bristol-Myers Squibb, National Cancer Institute, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

G protein-coupled receptor, class C, group 5, member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy was recently shown to be safe and active in patients with relapsed or refractory multiple myeloma with limited other therapeutic options. 1 Of the 17 patients treated in our phase 1 study of the GPRC5D-targeted CAR T-cell therapy MCARH109, 12 patients had an objective response and 6 patients had a relapse after an initial response of 3 to 9 months.Although no validated clinical assays to assess GPRC5D expression exist, we reported decreased or loss of protein expression using immunohistochemical analysis in all 6 patients who had a relapse. 1 This finding suggests that genetic alterations may be an important mechanism of antigen escape after GPRC5Ddirected CAR T-cell therapy.With the recently approved B-cell maturation antigen-directed CAR T-cell therapies, antigen loss due to genetic alterations appears to be a rare mechanism of resistance.2,3 We first investigated the genetic status of GPRC5D in a patient (Patient 15) who underwent biopsies of a plasmacytoma in the left posterior chest wall at baseline and a recurrent plasmacytoma at the same site at relapse with nearly 100% tumor.This patient received the maximum tolerated dose of 150×10 6 GPRC5D-directed CAR T cells and had a best response of stringent complete response without minimal residual disease in the bone marrow.Unfortunately, 6 months after infusion, he had a relapse in the chest and femur (Fig. 1A and 1B), extensive bone marrow involvement (90 to 95%), rapidly rising lambda free light-chain levels in the serum, and substantially decreased but still detectable circulating CAR T cells (CAR vector copies per milliliter, 666) (Fig. 1C).We performed a droplet digital polymerase-chain-reaction (PCR) assay on extracted DNA from the plasmacytoma biopsy samples and estimated the GPRC5D copy number to be 2 at baseline and 0.1 at relapse, findings consistent with biallelic loss in a substantial majority of plasma cells (Fig. 1D).We then performed whole-exome sequencing, which revealed two balanced copies of GPRC5D at baseline and biallelic loss at relapse consisting of a broader deletion (8.76 Mb) in chromosome 12p in one allele and a more focal deletion (145 kb) encompassing mailanks@mskcc.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveMultiple MyelomaReceptors, Chimeric AntigenHumansNeoplasm Recurrence, LocalReceptors, G-Protein-CoupledT-LymphocytesRecurrence

Substanzen

GPRC5D protein, humanReceptors, Chimeric AntigenReceptors, G-Protein-Coupled

Autor:innen und Institutionen

  • Memorial Sloan Kettering Cancer Center, New York, NY mailanks@mskcc.org.

Förderung

  • NCI NIH HHS
  • Bristol-Myers Squibb
  • National Cancer Institute, NIH

Zitieren

APA

Mi, X., Penson, A., Abdel-Wahab, O., & Mailankody, S. (2023). Genetic Basis of Relapse after GPRC5D-Targeted CAR T Cells. New England Journal of Medicine. https://doi.org/10.1056/nejmc2308544

Vancouver

Mi X, Penson A, Abdel-Wahab O, Mailankody S. Genetic Basis of Relapse after GPRC5D-Targeted CAR T Cells. New England Journal of Medicine. 2023. doi:10.1056/nejmc2308544

BibTeX
@article{Mi2023,
  author = {Mi, Xiaoli and Penson, Alex and Abdel-Wahab, Omar and Mailankody, Sham},
  title = {Genetic Basis of Relapse after GPRC5D-Targeted CAR T Cells},
  journal = {New England Journal of Medicine},
  year = {2023},
  doi = {10.1056/nejmc2308544}
}
Kostenlos starten →